PeptIQ app

Track your peptide protocols in PeptIQ

Log injections, calculate doses, and keep your library organized.

Get the appOpen web app

iOS, Android, and web

Research supplier

Retatrutide research materials

Retatrutide listings are for laboratory / research use only — not for human consumption.

Research use only. Partner link. PeptIQ may earn a referral fee. Not medical advice.

Tools for this page

Ask PeptIQ

Two taps on our guided quiz, then keep going in iMessage with sources — not Instagram screenshots.

Start the quizOr try Peptide X Quiz →
🔬

Audited August 3, 2026

✅Supported

The claim that retatrutide helps balance blood sugar is supported by human clinical trial evidence. Phase 2 data (Jastreboff et al., NEJM 2023) and Phase 3 results (TRIUMPH-4) in human subjects document retatrutide's metabolic effects, including improved glycemic control and insulin sensitivity, confirming the mechanism described. The claim accurately reflects the direction of available clinical evidence.

Share this audit

One link — full verdict, every claim, and PubMed citations included.

peptiq.io/check/f481ee73…

Shareable link includes the full verdict, claims, and PubMed citations.

Post captionshow

when taking igf1lr3 and cjc + ipa. u should have reta on the side to balance blood sugar

Claim breakdown

1 claim
1

“Reta (Retatrutide) helps balance blood sugar.”

✅Supported

Human Phase 2 clinical trial (Jastreboff et al., NEJM 2023, PMID: 37354027) demonstrates retatrutide's blood sugar-regulating effects via GLP-1/GIP/glucagon receptor agonism. Phase 3 data (TRIUMPH-4, December 2025) further confirms metabolic benefits including weight loss and improved insulin sensitivity, supporting the claim's mechanistic direction in human subjects.

Supporting studies

  1. 1

    GIPR:GCGR co-agonism restores normal weight in obese rodents

    Molecular metabolism · 2026·PMID 41997446

  2. 2

    Incretin-Based Weight Loss Pharmacotherapy: Can Resistance Exercise Optimize Changes in Body Composition?

    Diabetes care · 2024·PMID 38687506

  3. 3

    Retatrutide for the treatment of obesity, obstructive sleep apnea and knee osteoarthritis: Rationale and design of the TRIUMPH registrational clinical trials

    Diabetes, obesity & metabolism · 2026·PMID 41090431

  4. 4

    Retatrutide, a GIP, GLP-1 and glucagon receptor agonist, for people with type 2 diabetes: a randomised, double-blind, placebo and active-controlled, parallel-group, phase 2 trial conducted in the USA

    Lancet (London, England) · 2023·PMID 37385280

  5. 5

    Triple Agonism Based Therapies for Obesity

    Current cardiovascular risk reports · 2025·PMID 40741227

Audit another post

Instagram, TikTok, X, Reddit, or paste text directly.

New audit

Track your protocols

Dosing, logging, and reminders in the app.

Get the app

This audit is for educational purposes only. Not medical advice. Science evolves — always check citation dates and consult a qualified professional.

Report an error